Arthritis drug tested for Long-Term safety in kids

NCT ID NCT01673919

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at the long-term safety of the drug tocilizumab (Actemra) in 7 children with a type of arthritis called juvenile idiopathic arthritis. All children had already completed a previous study and continued to receive the drug every 4 weeks for up to 2 years. The main goal was to track any side effects or serious health issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab (brand name Actemra/RoActemra)
What this could lead to: If successful, this could confirm that long-term use of tocilizumab is safe for managing juvenile idiopathic arthritis in children.
What could go wrong: This is a very small extension study (7 people) with no comparison group, so results may not apply broadly. Side effects like infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE IDIOPATHIC ARTHRITIS

Contacts and locations

Locations

Study site

Le Kremlin-Bicêtre, 94275, France
Study site

Montpellier, 34295, France
Study site

Paris, 75679, France
Study site

Paris, 75743, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.